GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rallybio Corp (NAS:RLYB) » Definitions » EPS (Diluted)

Rallybio (Rallybio) EPS (Diluted) : $-1.87 (TTM As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Rallybio EPS (Diluted)?

Rallybio's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was $-0.47. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.87.

Rallybio's EPS (Basic) for the three months ended in Mar. 2024 was $-0.47. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.87.

Rallybio's EPS without NRI for the three months ended in Mar. 2024 was $-0.47. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.87.

During the past 3 years, the average EPS without NRIGrowth Rate was -15.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 5 years, Rallybio's highest 3-Year average EPS without NRI Growth Rate was -15.70% per year. The lowest was -27.40% per year. And the median was -21.55% per year.


Rallybio EPS (Diluted) Historical Data

The historical data trend for Rallybio's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rallybio EPS (Diluted) Chart

Rallybio Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
EPS (Diluted)
-1.01 -1.19 -1.84 -2.09 -1.84

Rallybio Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.43 -0.46 -0.45 -0.49 -0.47

Competitive Comparison of Rallybio's EPS (Diluted)

For the Biotechnology subindustry, Rallybio's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rallybio's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rallybio's PE Ratio distribution charts can be found below:

* The bar in red indicates where Rallybio's PE Ratio falls into.



Rallybio EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Rallybio's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as

Diluted EPS (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-74.564-0)/40.447
=-1.84

Rallybio's Diluted EPS for the quarter that ended in Mar. 2024 is calculated as

Diluted EPS (Q: Mar. 2024 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-19.029-0)/40.774
=-0.47

EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.87

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Rallybio  (NAS:RLYB) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Rallybio EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Rallybio's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Rallybio (Rallybio) Business Description

Traded in Other Exchanges
N/A
Address
234 Church Street, Suite 1020, New Haven, CT, USA, 06510
Rallybio Corp is a biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Its lead program is for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.
Executives
5am Partners V, Llc 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Kush Parmar director, 10 percent owner C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Jonathan I Lieber officer: See Remarks C/O HISTOGENICS CORPORATION, 830 WINTER STREET #3, WALTHAM MA 02451
Viking Global Investors Lp 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Ole Andreas Halvorsen 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
David C. Ott 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Portfolio Gp Llc 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Gp Llc 10 percent owner 55 RAILROAD AVENUE, GREENWICH CT 06830
Viking Global Opportunities Illiquid Investments Sub-master Lp 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Rose Sharon Shabet 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Parent Gp Llc 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Wendy Chung director PRIME MEDICINE, INC., 21 ERIE ST., CAMBRIDGE MA 02139
5am Opportunities I, L.p. 10 percent owner 501 SECOND STREET, SUITE 350, SAN FRANCISCO CA 94107
Hui Liu director C/O MERUS N.V., YALELAAN 62, UTRECHT P7 3584 CM
Christine A Nash director C/O RALLYBIO CORPORATION, 234 CHURCH STREET, SUITE 1020, NEW HAVEN CT 06510